PharmaDeals Review Business Commentaries
Dr Fintan Walton, PharmaVentures’ CEO, provides monthly comment on topical biotechnology and pharmaceutical industry issues. Includes access to Fintan’s commentaries broadcast on PharmaTelevision.
Available as PDF
(Subscribers only)
Therapy focus: Osteoarthritis
From issue 91 of the PharmaDeals Review (2008-01-01)
This feature discusses the various approaches that have been, and are being, taken towards alleviating pain in and treating the condition of osteoarthritis. The article is in four parts. The first reviews the pain relief drugs that are already on the market and are in development for osteoarthritis, and the second discusses progress towards various disease-modifying therapeutics – which may be just chondroprotective, or may even help to build up cartilage; development work being advanced by Galapagos and Medivir is described. The last two parts of the article look at the preventive approach (work on biomarkers), and at the use of stem cells.
Available as PDF
(Subscribers only)
Galapagos' Latest Advance: Its Licensing Deal with Janssen
From issue 90 of the PharmaDeals Review (2007-12-01)
On the back of the successful building of its service division, BioFocus DPI, Galapagos has licensed its rheumatoid arthritis programme to Janssen Pharmaceutica (of Johnson and Johnson) in highly lucrative deal that could earn the company in excess of US$1 B. Following an exclusive interview with Onno van de Stolpe, CEO of Galapagos, the article discusses the significance of the deal and the strategy of the company going forward.
Available as PDF
(Subscribers only)
Pfizer Acquires Immunology Company Coley
From issue 90 of the PharmaDeals Review (2007-12-01)
Pfizer has entered into an agreement to acquire immunotherapy company Coley Pharmaceutical Group, for US$164 M. Based on its Toll-like receptor technology, Coley has developed drug candidates for the treatment of various diseases - including cancer, asthma and allergy, and autoimmune diseases, as well as adjuvants to enhance the effectiveness of vaccines. The article looks at the company's pipeline and previous collaborations, and discusses events at Coley leading up to the deal with Pfizer.
Available as PDF
(Subscribers only)
Alzheimer's - A Great Deal Still to be Done
From issue 90 of the PharmaDeals Review (2007-12-01)
Based on current prevalence statistics, if you make it into your nineties, then dementias, predominantly Alzheimer's disease (AD), are likely to affect around one in three of us. AD is, in fact, the seventh biggest killer of all ages in the US. This article, by Nigel Borshell, looks at the initial identification of the disease, the various suggestions that have been made as to its causes, treatments that are likely to show promise, and currently hypothesised toxins and possible targets.
Available as PDF
(Subscribers only)
Therapy Focus: Alzheimer's Disease
From issue 90 of the PharmaDeals Review (2007-12-01)
The worldwide cost of dementia care is estimated to be US$315.4 B annually. In the US, the care costs for Alzheimer's disease (AD) have been estimated at over US$100 B, and a 20007 study put the cost in the UK at £17.03 B (US$34 B). This Therapy Focus, by Nigel Borshell, looks at the need for the early diagnosis of AD, possible disease markers, the requirement for advances in pharmacoeconomic aspects, and recent deal making and opportunities. It also provides details of current R&D projects.
Review and Analysis, Navigation
Bookmarks
Bookmark PharmaDeals through one of these social networks.
